lung cancer

[Cell Death & Disease] Scientists showed that ubiquitin specific peptidase 5 (USP5) was a novel PD-L1 deubiquitinase in non-small cell lung cancer (NSCLC) cells. USP5 directly interacted with PD-L1 and deubiquitinated PD-L1, therefore enhances PD-L1 protein stability.

[Oncology Letters] The molecular mechanism underlying the role of FOXD3‑AS1 in cancer development has not yet been fully elucidated. Researchers focused on non‑small cell lung cancer in order to gain insight into how FOXD3‑AS1 drives cancer progression.

[Oncology Letters] High PLOD1 mRNA levels have been determined to be prognostically significant in numerous human malignancies. Researchers elucidated the pathological mechanism of procollagen‑lysine, 2‑oxoglutarate 5‑dioxygenase 1 in lung cancer.

[Galecto, Inc.] Galecto, Inc. announced that it has entered into a clinical trial supply agreement with Roche to explore the combination of GB1211, Galecto’s oral galectin-3 inhibitor, with Roche’s PD-L1 checkpoint inhibitor atezolizumab in Galecto’s planned Phase IIa trial in non-small-cell lung cancer

[Cancer Cell International] The authors investigated the role of ASAP1 Intronic Transcript 1 (ASAP1-IT1) in cancer cell stemness of non-small cell lung cancer.

[Cancer Medicine] The function of CAMSAP3 on the regulation of cellular senescence-associated phenotypes in human non-small cell lung cancer H460 cells were determined in CAMSAP3 deletion (H460/C3ko) cells.